MB Comment: Merck just announced Q4 2011 and full year revenues and earnings. Gardasil is now Merck’s 10th largest product by volume, with sales growth of 22%, vs. Merck’s flat total revenue growth of 4%. Merck’s strategy of cramming this toxic vaccine (Gardasil) into as many unwilling victims as possible is a huge financial success.
Merck is working on a new improved version of Gardasil with more HPV strains, since the current version only covers 4 strains (25% of total HPV strains). The market for booster shots of new improved Gardasil for those who have already received the old obsolete version should continue rapid growth for this vaccine.
What a brilliant marketing strategy. Introduce an ineffective and toxic vaccine, use fear of developing cancer in 20 years to enlarge the market, deny causation for those who die or suffer permanent neurological damage from Gardasil, hide behind the National Vaccine Compensation Program so victims cannot sue the perpetrator — and then introduce a new improved version of Gardasil to pump more doses into those who already fell for the BS obsolete Gardasil sales pitch. Most sheeple won’t realize they’ve been had until some of them die or develop seizures and paralysis.
Congratulations to Merck for the great financial success of their Orwellian Gardasil marketing campaign.
They have taken a page directly out of their Vioxx manual, a drug that killed about 40,000 people before it was pulled from the market. For that, Merck pled guilty to a criminal charge and paid a $950 million fine.
************************************************************************************************
press release Feb. 2, 2012
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
“We are positioning Merck to perform well by advancing and growing our innovative pipeline, meeting the evolving needs of customers around the world and achieving a more efficient operating model,” said Kenneth C. Frazier, chairman and chief executive officer of Merck. “We closed out 2011 with a high-quality fourth quarter by growing the top and bottom lines. Our overall performance for the year confirms our ability to achieve strong operating results while investing for the longer term. As we begin 2012 and look ahead, we are optimistic about our underlying business, our current momentum and the early success of our strategy.”
Full-year 2011 worldwide sales were $48.0 billion, an increase of 4 percent … The revenue increases largely reflect strong sales of … GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant].
2011 % change from 2011
Total Sales $48.1 Bil +4%
GARDASIL $1.21 Bil +22%
Sales of GARDASIL, a vaccine to help prevent certain diseases caused by four types of human papillomavirus (HPV), were $274 million, an increase of 24 percent for the quarter driven by increased vaccination of males ages 9 through 26. Worldwide sales of GARDASIL for the year were $1.2 billion, a 22 percent increase compared with the prior year …
